Improve and save patient lives
Faster, targeted treatment means a better chance of survival, fewer complications, and safer recovery with less exposure to unnecessary antibiotics.
No one should die from a treatable infection.
Delphine Diagnostics is building rapid molecular diagnostics and AI/ML-enabled clinical decision support to help clinicians recognize sepsis risk earlier, identify pathogens and resistance markers sooner, and treat patients with greater precision.
#1Cause of death in U.S.
hospitals
80%Of deaths may be
preventable with timely care
8%Mortality increase for every
hour of delay
350KU.S. deaths per year
attributed to sepsis
Source: US CDC
Delphine's Comprehensive Approach
Sepsis care is constrained by diagnostic uncertainty, slow culture workflows, and the need to choose effective antimicrobial treatment quickly. Delphine combines rapid molecular testing with clinical risk intelligence to support better decisions earlier in the patient journey.
Faster, targeted treatment can change the patient journey.
01Patients
02Health Care Providers
03Insurers
04Hospitals
Reduce diagnostic uncertainty
Rapid answers and early risk signals empower clinicians to intervene sooner, choose the right therapy, and reduce diagnostic uncertainty.
Improve outcomes and lower cost of care
Preventing deterioration and avoiding broad-spectrum overtreatment can reduce high-cost admissions, readmissions, and downstream complications.
Shorten length of stay and improve quality
Earlier detection and optimized antibiotic use can lower ICU burden, shorten length of stay, reduce readmissions, and improve quality metrics.
A connected portfolio for infection diagnosis, treatment support, and ongoing research initiatives.
Delphine's roadmap includes SepSeek, ClinSight, PathoVue, and RUO pathogen identification assays.
SepSeek Sepsis Diagnostic Test Kits
A PCR-based assay for rapid detection of pathogen and host markers to support personalized patient care.
- Targets pathogen identification
- Plans for resistance marker expansion
- Designed around standard clinical lab equipment
ClinSight Sepsis Prediction
Machine-learning software intended to help clinicians identify patients at risk of developing sepsis or readmission.
- EHR-embedded alert vision
- Explainable risk context
- Snapshot and forecast modeling
PathoVue
An ongoing research initiative focused on pathogen intelligence, visibility, and actionable infectious disease insights.
- Supports pathogen-focused research
- Designed for clearer infectious disease context
- Built to complement Delphine's diagnostic portfolio
RUO Pathogen Identification Kits
Real-time PCR assays for organisms including E. coli, S. aureus, K. pneumoniae, and A. baumannii.
- Environmental monitoring
- Food safety research
- Microbiological studies
SepSeek Workflow Comparison
SepSeek is Delphine's PCR-based assay concept for bacterial, viral and fungal pathogen identification and resistance biomarkers. The workflow is designed to be 6-9 times faster than conventional blood culture.
Conventional Blood Culture
Conventional blood culture can take 1-7 days for results
36-72 hours
- Blood Collection (20ml)
- Blood Culture
- Bacteria Culture
- Bacteria ID
- Antimicrobial Sensitivity
- Pathogen ID + Resistance
SepSeek PCR Workflow
SepSeek results are available in under 8 hours
6-8 Hrs
- Blood Collection (1ml)
- DNA Extraction
- Multiplex RT-PCR
- Data Analysis and Interpretation
- Pathogen ID + Resistance
SepSeek & CDSA
Partners and Allies
Help bring faster sepsis diagnosis closer to the point of care.
Delphine is interested in hearing from future customers, clinical partners, laboratories, and healthcare organizations about diagnostic targets, compatible equipment, and workflow needs.